MFDS Forms 'CellUp' Consultative Body to Support Regulation for Commercialization of Advanced Biopharmaceutical Products

The Ministry of Food and Drug Safety's National Institute of Food and Drug Safety Evaluation announced on the 4th that it has formed a consultative body called 'CELL-UP' together with institutions supporting the commercialization of advanced biopharmaceutical products to provide regulatory support.

CELL-UP serves the role of providing customized regulatory consulting tailored to the needs of users.

The institutions participating in CELL-UP, in addition to the National Institute of Food and Drug Safety Evaluation, include the Pan-Government Regenerative Medicine Technology Development Project Group, Osong Medical Innovation Foundation, Regenerative Medicine Promotion Foundation, Korea Center for Regulatory Science, and Korea Biopharmaceutical Association, totaling five organizations.

Next year, they plan to hold meetings for researchers and developers, share each institution's schedules, and create a regulatory support project calendar for advanced biopharmaceuticals. They also plan to conduct surveys for the development of customized support programs.

Park Yoon-joo, President of the National Institute of Food and Drug Safety Evaluation, stated, "The six institutions playing a central role in the regulatory support project will communicate and cooperate closely to actively support the commercialization of domestic advanced biopharmaceuticals and their entry into the global market."

This content was produced with the assistance of AI translation services.